Q2 FY26 Results: Revenue Down 17%, PAT Falls 52% YoY

Revenue declinedEBITDA margin compressionResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹99.25

prior close

₹96.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-5.2% vs market

Pharmaceuticals peers, median of 157sector+0.0%-5.3% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.5

15m

+1.5

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3-0.1-5.2+0.0-5.3

Next day

-5.3+0.5-5.8-0.1-5.2

-4.8-0.3-4.5-0.9-3.9

-6.3-0.5-5.8-1.3-5.0

-7.3-0.8-6.5-1.6-5.7

-7.2-2.3-4.9-2.3-4.9

-9.4-2.8-6.6-2.9-6.5

15d

-2.8-4.9+2.1-3.6+0.8

+1.8-4.7+6.5-4.4+6.1

-6.8-7.7+0.9-5.6-1.2

-0.3-7.8+7.6-10.7+10.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals reported Q2 FY26 standalone revenue of Rs 2,865.89 lakhs, down 17.3% YoY from Rs 3,465.69 lakhs. PAT fell 52% to Rs 412.96 lakhs (vs Rs 859.58 lakhs YoY). H1 FY26 revenue declined 4.5% to Rs 5,470.53 lakhs with PAT at Rs 745.77 lakhs, down 33% YoY. EPS for the quarter was Rs 3.36. Company remains debt-free with cash and equivalents of Rs 3,385.56 lakhs. EBITDA margins compressed sharply. Limited review report was clean with no qualifications.

Likely market impact

Weak quarterly performance with sharp revenue and profit decline. Debt-free balance sheet with strong cash provides cushion, but margin pressure is a concern.